

AVN-944

Catalog No: tcsc3427



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

297730-17-7

Formula:

$C_{25}H_{27}N_5O_5$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

DMSO : \geq 31 mg/mL (64.92 mM)

Alternative Names:

VX-944

Observed Molecular Weight:

477.51


Product Description

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with K_i of 6-10 nM for IMPDH1/IMPDH2.

IC50 value: 6-10 nM (K_i) [1]

Target: IMPDH

in vitro: AVN-944 strikingly inhibit RNA synthesis within 2 h of exposure. Depletion of guanine nucleotides by MPA and AVN-944 also causes an early and near-complete reduction in levels of the 45S precursor rRNA synthesis and the concomitant translocation of nucleolar proteins including nucleolin, nucleophosmin, and nucleostemin from the nucleolus to the nucleoplasm [2]. AVN944 induced caspase-dependant and caspase-independent cell death in LNCaP, CWR22Rv1, and DU145 cells. AVN944 induced expression of p53-target proteins Bok, Bax and Noxa in androgen-responsive cell lines and suppressed expression of survivin in prostate cancer cells regardless of their androgen sensitivity. AVN944 also induced differentiation of androgen-independent prostate cancer cells as indicated by morphological changes and increased expression of genes coding for prostasomal proteins, keratins and other proteins, including tumor suppressor genes MIG-6 and NDRG1. AVN944-differentiated androgen-independent DU145 and PC-3 cells are sensitized to TRAIL-induced apoptosis as demonstrated by induction of caspases and PARP cleavage [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!